CYP3A4 and type 2 diabetes mellitus: In clinical practice, this is especially relevant because patients with type 2 diabetes mellitus often receive multiple medications for comorbidities such as dyslipidemia, hypertension, and cardiovascular disease [124], increasing the risk of drug–drug interactions [125] and interindividual variability due to genetic polymorphisms affecting CYP3A4 expression or function.